Gauthier S, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomized, controlled, double-blind, parallel-arm, phase 3 trial. The Lancet 2016. Available at: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31275-2/fulltext Accessed 16 November 2016

Download

Lai RYK, Harrington CR, and Wischik CM. (2016) Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease. Biomolecules 6(2).

Download

Vuksanovic V, Staff RT, Ahearn T, et al. (2016) Frontotemporal atrophy and clinical estimates of disease severity in behavioural variant frontotemporal dementia: The role of cognitive reserve. Presented at the Alzheimer’s Research UK Conference, Manchester, UK.

Šimic G, Babic M, et al. (2016) Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other tauopathies, and possible neuroprotective strategies. Biomolecules 6(1).

Download

Harrington CR, Storey JMD, Clunas S, et al. (2015) Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease. J Biochem Pharmacol 290(17):10862-10875.

Download